The National Center at the Second Edition of the Italy–US Tech Business and Investment Matching Initiative, Washington, D.C.

The panel addressed several key issues shaping the future of the biotechnology and pharmaceutical industries. It highlighted the need to promote joint research initiatives and transatlantic clinical trials focused on developing vaccines and advanced therapies, thereby strengthening collaboration between Europe and the United States.

Ample space was also devoted to green biotechnology and strategies for making pharmaceutical production more sustainable, with the aim of reducing the industry’s environmental impact. Another crucial issue concerned the need to build resilient supply chains capable of ensuring the continuous availability of active ingredients and medical devices, even during times of crisis.

The panel further explored how the digital transformation of clinical research, driven by artificial intelligence and big data, can accelerate experimental processes and enhance the quality of data analysis. Finally, participants stressed the need for effective incentives to support biotechnology startups and scale-ups, fostering innovation and driving the growth of new enterprises across the sector.

The Initiative also featured the launch of the Transatlantic Venture Platform, presented at the Atlantic Council in partnership with CDP Venture Capital SGR, Italian Tech Alliance, and more than 30 venture capital firms from both countries. This platform aims to catalyze cross-border investments and collaborative projects in strategic sectors such as biotechnology, aerospace, and sustainable technologies.

Prof. Cosma’s participation contributed to promoting the National Center’s mission of advancing innovation in gene therapy and RNA-based technologies, and fostering international collaboration to accelerate the translation of scientific research into tangible health and industrial solutions. His intervention underscored the role of the Center as a strategic player in building resilient and sustainable biomedical value chains through cooperation between Italy and the United States.